NICE will not be a problem. NWBO has been in discussions with them for years and both sides know where the other stands. NICE knows that DCVax-L is a game-changer in all areas of oncology and that agreement must be reached with the Company. It will bend over backwards to reach an agreement but that doesn't mean that it will agree to a stupidly excessive price, something of which the Company will be aware. I have no doubt that it will pitch a realistic price, knowing that once that is agreed the floodgates will be open as far as the rest of the world is concerned. Anglers do it all the time - its called "casting your bread upon the waters" (Ecclesiastes 11).
Market Data 
Markets 
AI
